Comparative Effectiveness of Denosumab versus Alendronate Among Postmenopausal Women with Osteoporosis in the US Medicare Program

被引：0
|
作者：
Curtis, Jeffrey [1 ]
Arora, Tarun [2 ]
Liu, Ye [1 ]
Lin, Tzu-Chieh [3 ]
Spangler, Leslie [3 ]
Brunetti, Vanessa C. [3 ]
Stad, Robert K. [3 ]
McDermott, Michele [3 ]
Bradbury, Brian D. [3 ]
Kim, Min [3 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] Fdn Adv Sci Technol Educ & Res, Birmingham, AL USA
[3] Amgen Inc, Thousand Oaks, CA USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2023年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2008
引用
收藏
页码：3979 / 3981
页数：3
相关论文
共 50 条
  • [41] ALENDRONATE DISCONTINUATION IN POSTMENOPAUSAL WOMEN TREATED FOR OSTEOPOROSIS
    Powell, Diane
    Than, Soe Soe
    Butler, Robin
    Matthews, Clare
    Garton, Mark
    RHEUMATOLOGY, 2014, 53 : 133 - 134
  • [42] Cyclical alendronate treatment in postmenopausal women with osteoporosis
    Kösüs, A
    Çapar, M
    Kösüs, N
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2005, 91 (02) : 182 - 184
  • [43] Alendronate improves QOL of postmenopausal women with osteoporosis
    Kawate, Hisaya
    Ohnaka, Keizo
    Adachi, Masahiro
    Kono, Suminori
    Ikematsu, Hideyuki
    Matsuo, Hisashi
    Higuchi, Kazumi
    Takayama, Takehiko
    Takayanagi, Ryoichi
    CLINICAL INTERVENTIONS IN AGING, 2010, 5 : 123 - 131
  • [44] The comparative effect of teriparatide and denosumab on activins, follistatins, and inhibins in women with postmenopausal osteoporosis
    Anastasilakis, Athanasios D.
    Polyzos, Stergios A.
    Makras, Polyzois
    Savvidis, Matthaios
    Mantzoros, Christos S.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2024, 39 (09) : 1306 - 1314
  • [45] Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
    Le, Quang A.
    Hay, Joel W.
    Becker, Russell
    Wang, Yamei
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (02) : 134 - 143
  • [46] Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    Jonsson, B.
    Strom, O.
    Eisman, J. A.
    Papaioannou, A.
    Siris, E. S.
    Tosteson, A.
    Kanis, J. A.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (03) : 967 - 982
  • [47] DENOSUMAB SIGNIFICANTLY INCREASES BMD COMPARED WITH ALENDRONATE IN POSTMENOPAUSAL WOMEN
    Galesanu, C.
    Lisnic, N.
    Moisii, L.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S150 - S150
  • [48] Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis
    B. Jönsson
    O. Ström
    J. A. Eisman
    A. Papaioannou
    E. S. Siris
    A. Tosteson
    J. A. Kanis
    Osteoporosis International, 2011, 22 : 967 - 982
  • [49] Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
    Kendler, D. L.
    McClung, M. R.
    Freemantle, N.
    Lillestol, M.
    Moffett, A. H.
    Borenstein, J.
    Satram-Hoang, S.
    Yang, Y. -C.
    Kaur, P.
    Macarios, D.
    Siddhanti, S.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (06) : 1725 - 1735
  • [50] Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate
    D. L. Kendler
    M. R. McClung
    N. Freemantle
    M. Lillestol
    A. H. Moffett
    J. Borenstein
    S. Satram-Hoang
    Y.-C. Yang
    P. Kaur
    D. Macarios
    S. Siddhanti
    Osteoporosis International, 2011, 22 : 1725 - 1735
12345